Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.
The present disclosure relates to the field of transdermal delivery patches containing dexmedetomidine and use of the transdermal delivery patches for treating pain, e.g., post-operative pain.
The present disclosure relates to the field of transdermal delivery patches containing dexmedetomidine and use of the transdermal delivery patches for treating pain, e.g., post-operative pain.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Poultices, pharmaceutical preparations for the treatment of pain, central nervous system disorders, and dermatological conditions; reagent paper for medical purposes, oiled paper for medical purposes, adhesive tapes for medical purposes, wrapping wafers for medicine doses being drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals, gauze for dressings, empty capsules for pharmaceuticals, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton for medical purposes, adhesive plasters for medical purposes, bandages for dressings, antiseptic liquid bandages, breast-nursing pads, cotton swabs for medical use, dental impression materials, fly catching paper, mothproofing paper
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Poultices, pharmaceutical preparations for the treatment of pain, central nervous system disorders, and dermatological conditions; reagent paper for medical purposes, oiled paper for medical purposes, adhesive tapes for medical purposes, wrapping wafers for medicine doses being drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals, gauze for dressings, empty capsules for pharmaceuticals, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton for medical purposes, adhesive plasters for medical purposes, bandages for dressings, antiseptic liquid bandages, breast-nursing pads, cotton swabs for medical use, dental impression materials, fly catching paper, mothproofing paper
The present disclosure relates to the field of transdermal delivery patches containing dexmedetomidine and use of the transdermal delivery patches for treating pain, e.g., post-operative pain.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 25/00 - Drugs for disorders of the nervous system
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical products, namely analgesics; anesthetic topical dermatological preparations; pharmaceutical preparations, namely analgesics Providing online information on the subjects of pharmaceutical preparations and techniques
9.
LOXOPROFEN-CONTAINING ADHESIVE PATCH AND METHOD FOR MANUFACTURING SAME
The present invention provides a patch that suppresses the generation of a degradation product of loxoprofen and shows excellent skin permeability, and a method for producing the same. Specifically, the present invention provides a patch comprising loxoprofen or a salt thereof, or a hydrate thereof; a C2-C6 hydroxy acid; and a metal oxide in a pasty preparation, and a method for producing the same.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
10.
METHODS AND COMPOSITIONS FOR MANAGING PAIN COMPRISING DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS
Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
The present invention provides a transdermally absorbable preparation which demonstrates the same level of pharmacokinetics and therapeutic effect as does orally administered donepezil. The present invention specifically provides a transdermally absorbable preparation for treating dementia which has an adhesive layer containing donepezil free base, said adhesive layer containing a styrene-isoprene-styrene block copolymer and 13.75 -55mg of donepezil free base. The preparation is to be administered to a patient once per day.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
12.
TOPICAL NALOXONE COMPOSITIONS AND METHODS FOR USING THE SAME
Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.
The present invention provides a patch which prevents ketoprofen from forming a menthol ester, suppresses crystal precipitation, and yet shows excellent skin permeability. Specifically, the present invention provides a patch comprising ketoprofen, L-menthol, zinc oxide, and a fatty acid ester in a pasty preparation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations in the nature of topical and oral preparations, transdermal patches, medical dressings and medical adhesive tapes for treating cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, inflammation, skin conditions, infectious diseases, asthma, hormonal imbalance and pain; dietary and nutritional supplements; laxative suppositories; enema preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Transdermal patches for use in the treatment of attention
deficit hyperactivity disorder, anxiety insomnia, or
withdrawal syndromes; transdermal patches for use in the
management of pain; transdermal patches for use in providing
sedation; pharmaceutical preparations, namely, topical
preparations for use in the treatment of attention deficit
hyperactivity disorder; pharmaceutical preparations, namely,
topical preparations for use in the treatment of anxiety,
pharmaceutical preparations, namely, topical preparations
for use in the treatment of insomnia; pharmaceutical
preparations, namely, topical preparations for use in the
treatment of withdrawal syndromes; topical preparations for
use in the management of pain; topical preparations for use
in providing sedation.
17.
Topical naloxone compositions and methods for using the same
Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.
The purpose of the present invention is to provide an aqueous patch in which basic physical properties as an aqueous patch are less likely to deteriorate and crystals of 1-menthol are less likely to precipitate. The aqueous patch includes, in a pasty preparation, 1-menthol: 0.5% by mass or more and 10% by mass or less, an oil component: 0.2% by mass or more and 19% by mass or less; and silica: 0.1% by mass or more and 5.5% by mass or less.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
22.
LOXOPROFEN-CONTAINING ADHESIVE PATCH AND METHOD FOR MANUFACTURING SAME
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention provides a patch that prevents ketoprofen from forming menthol ester, suppresses crystal deposition and yet shows excellent skin permeability. More particularly, the present invention provides a patch that contains ketoprofen, L-menthol, zinc oxide and a fatty acid ester in a plaster.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.
The purpose of the present invention is to provide a rivastigmine-containing transdermal absorption preparation having high adhesion to the skin and capable of continuously administering rivastigmine over a long period of time. A transdermal absorption preparation has rivastigmine, a rubber polymer, a tackifier resin, and a polymer compound having a nitrogen-containing group.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Provided is a water-based adhesive patch which has basic physical properties required of a water-based adhesive patch that are less apt to deteriorate and in which crystals of l-menthol are less apt to separate out. This water-based adhesive patch includes a plaster which contains 0.5-10 mass% l-menthol, 0.2-19 mass% oil, and 0.1-5.5 mass% silica.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
The present invention provides a testosterone-containing transdermal formulation having excellent skin permeability of testosterone and excellent formulation properties. Specifically, the present invention provides a transdermal formulation comprising testosterone; polyacrylic acid or a salt thereof; a thickener; a cross-linking agent; a plasticizer comprising propylene glycol; and a lactic acid ester in a pasty preparation.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
10 - Medical apparatus and instruments
11 - Environmental control apparatus
Goods & Services
Cosmetics; skin sheet masks for cosmetic use; beauty masks; cosmetic facial masks; cosmetic masks Cooling sheets for medical purposes applied to affected areas Chemically-activated cooling sheets for cooling the body and not for medical purposes
The present invention provides a risperidone-containing patch having an excellent drug release property and patch physical properties. Specifically, the present invention provides a medical patch comprising an adhesive composition comprising risperidone or a pharmaceutically acceptable salt thereof; a carboxylic acid; a fatty acid ester; and an adhesive, characterized in that said adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a sulfur residue of a mercapto group situated at the center, wherein the (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.99% by mass of the whole structural units in said star-shaped acrylic block polymer, and at least one of said chain polymer portions has a structural unit having a copolymer structure of polymerizable monomers comprising a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a polyfunctional monomer.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
32.
Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
[Problem] To provide: a flurbiprofen-axetil-containing fat emulsion that, even though the fat-and-oil content is high so that the fat emulsion can carry a large amount of flurbiprofen axetil, possesses transparency and excellent stability, and that additionally achieves excellent safety as a result of employing lecithin as an emulsifier; and a method for manufacturing said flurbiprofen-axetil-containing fat emulsion. [Solution] A flurbiprofen-axetil-containing fat emulsion according to the present invention includes at least flurbiprofen axetil, fat and oil, an emulsifier, and an aqueous medium as constituent components, the flurbiprofen-axetil-containing fat emulsion being characterized in that: the fat-and-oil content is 3-50 mg/mL; the weight ratio (flurbiprofen axetil/fat and oil) of the flurbiprofen axetil with respect to fat and oil is 0.1-5 (where the total content of the flurbiprofen axetil and fat and oil is 100 mg/mL at maximum); the content of lecithin, which serves as the emulsifier, is 20-150 mg/mL (50 wt% or less of the lecithin to be employed may be replaced with an emulsifier other than lecithin); and the turbidity is 0.5 or less.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Transdermal patches for use in the treatment of attention deficit hyperactivity disorder, anxiety insomnia, or withdrawal syndromes; transdermal patches for use in the management of pain; and transdermal patches for use in providing sedation; pharmaceutical preparations, namely, topical preparations for use in the treatment of attention deficit hyperactivity disorder, anxiety insomnia, or withdrawal syndromes; topical preparations for use in the management of pain; and topical preparations for use in providing sedation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Transdermal patches for use in the treatment of attention deficit hyperactivity disorder, anxiety insomnia, or withdrawal syndromes; transdermal patches for use in the management of pain; and transdermal patches for use in providing sedation; pharmaceutical preparations, namely, topical preparations for use in the treatment of attention deficit hyperactivity disorder, anxiety insomnia, or withdrawal syndromes; topical preparations for use in the management of pain; and topical preparations for use in providing sedation.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics. Prescription and over-the-counter pharmaceutical
preparations, namely topical formulations, transdermal
patches, dressings and medical tapes for use with humans and
animals.
The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation.
Naloxone transdermal delivery devices are provided. Aspects of the naloxone transdermal delivery devices include a matrix comprising a naloxone active agent in a pressure sensitive adhesive and a backing layer. Also provided are methods of making and using the naloxone transdermal delivery devices, as well as kits containing the transdermal delivery devices. The devices, kits and methods of using the same find use in a variety of applications.
Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, topical formulations for treatment of inflammation; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, transdermal patches for treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, skin conditions, infectious diseases, asthma, hormonal imbalance, and pain; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical and surgical dressings; prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical adhesive tapes
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a transdermally administrable preparation which contains testosterone, a polyacrylic acid or a salt thereof, a thickening agent, a cross-linking agent, a plasticizer containing propylene glycol and a lactic acid ester in a plaster.
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence
A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided is a rivastigmine-containing percutaneous absorption-type preparation which has high adhesion to skin and which allows rivastigmine to be sustainably administered for a long period of time. The percutaneous absorption-type preparation is characterized by containing a polymer compound having rivastigmine, a rubber polymer, tackifying resin, and a nitrogen-containing group.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A receiving container includes a container body and a grip member. The container body includes: a body portion in a hollow tubular shape; a bottom portion configured to close one end side opening portion of the body portion; and a ceiling portion configured to close another end side opening portion of the body portion. One of a first extending portion and a second extending portion of the ceiling portion has a separation portion configured to separate a tip portion. The grip member includes: attachment portions, and a grip portion grippable by hand. The attachment portions are configured to prevent the first extending portion and the second extending portion from opening from the other end side opening portion. The attachment portions are attached to a tip side of the separation portion in either of the first or second extending portion provided with the separation portion.
B65D 5/54 - Lines of weakness to facilitate opening of container or dividing it into separate parts by cutting or tearing
B65D 5/02 - Rigid or semi-rigid containers of polygonal cross-section, e.g. boxes, cartons or trays, formed by folding or erecting one or more blanks made of paper by folding or erecting a single blank to form a tubular body with or without subsequent folding operations, or the addition of separate elements, to close the ends of the body
An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
The present invention provides a risperidone-containing patch endowed with both excellent drug releasability and patch physical properties. Specifically, the present invention provides a medical patch that includes risperidone or a pharmaceutically acceptable salt thereof, a carboxylic acid, a fatty acid ester, and an adhesive composition including an adhesive, wherein the medical patch is characterized in that the adhesive is a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain-form polymer moieties extend radially from a sulfur residue of a mercapto group in the center, 30-99.99 mass% of the total structural units of the star-shaped acrylic block polymer are C7-17 (meth)acrylic acid alkyl ester units, and at least one of the chain-form polymer moieties is a structural unit having a copolymer structure of a C7-17 (meth)acrylic acid alkyl ester and a polymerizable monomer including a polyfunctional monomer.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
C09J 7/20 - Adhesives in the form of films or foils characterised by their carriers
A61K 9/00 - Medicinal preparations characterised by special physical form
Provided is a transdermal preparation containing rivastigmine, which is capable of continuously administering an active ingredient that is rivastigmine for a long time, and which has low skin irritancy. A transdermal preparation according to the present invention contains, in mass%, from 5% to 30% (inclusive) of rivastigmine, from 10% to 60% (inclusive) of a rubber adhesive and from 30% to 70% (inclusive) of a tackifying resin; and if a (%) is the content of the rivastigmine, b (%) is the content of the rubber adhesive and c (%) is the content of the tackifying resin, a, b and c satisfy formulae (1) and (2). a + c ≥ 55 (1) b/c ≤ 1.00 (2)
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
50.
Rivastigmine transdermal compositions and methods of using the same
Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.
Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.
Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
The present invention provides a water-based adhesive patch which can stably contain only one of the optical isomers, S- and R-isomers, of a drug in a relatively high concentration over a long period and which has excellent tackiness and shape retentivity and, despite this, enables the drug to highly permeate the skin. Specifically, the present invention provides a water-based adhesive patch including a plaster which contains only one of the optical isomers of a drug as an active ingredient.
The purpose of the present invention is to provide a transdermal absorption-type patch preparation comprising zonisamide, said transdermal absorption-type patch preparation comprising zonisamide or an alkali metal salt thereof as zonisamide or an alkali metal salt thereof, being capable of holding a high concentration of the drug in a dissolved state therein and exerting a sufficient and long-lasting drug effect. A transdermal absorption-type patch preparation that comprises an adhesive layer, said adhesive layer comprising zonisamide or an alkali metal salt thereof, an adhesive agent comprising a (meth)acrylic copolymer having a pyrrolidone group, and a transdermal absorption promoter comprising an N-alkylpyrrolidone.
The present invention provides: a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9 mass% of all structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers including a weak basic monomer and (meth)acrylic acid alkyl ester having 7-17 carbon atoms; and a medical adhesive patch that exhibits high efficacy, that causes less skin irritation and does not cause a decrease in adhesive properties of the adhesive base due to additives, and that contains a salt of a basic drug and an adhesive agent composition containing the star-shaped acrylic block polymer as an adhesive agent.
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
Provided is a novel transdermal absorption preparation containing silodosin or tamsulosin, or salt thereof as an active ingredient, wherein the transdermal absorption preparation is capable of keeping a dissolved state for a long time, as well as has a high permeability to a skin, and can effectively and sustainably exert the transdermal absorbability. A transdermal absorption preparation containing the transdermal absorption preparation comprises an acrylic pressure-sensitive adhesive that comprises a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer and that contains a carboxyl group, and at least one transdermal absorption promoting agent selected from the group consisting of oleyl alcohol, lauryl alcohol, and lauromacrogol.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.
The present invention is provided with a container body 4 and a grip member 5. The container body 4 has a hollow cylindrical trunk part 1, a bottom part 2 for closing off a one-end-side opening of the trunk part 1, and a top part 3 for closing off an other-end-side opening of the trunk part 1. The top part 3 has a first extending part 17d and a second extending part 17b extending from the edges of the other-end-side opening. A separation part 25 for detaching a distal-end portion is formed on the first extending part 17d or the second extending part 17b. The grip member 5 has attachment parts 31 and a grip part 30 that can be manually gripped. The attachment parts 31 prevent the first extending part 17d and the second extending part 17b from opening from the other-end-side opening. The attachment parts 31 are attached to the extending part 17b or 17d on which the separation part 25 is formed, the attachment parts 31 being closer to the distal end than is the separation part 25.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics. Prescription and over-the-counter pharmaceutical
preparations, namely topical formulations, transdermal
patches, dressings and medical tapes for use with humans and
animals.
Provided is a patch preparation that has improved adhesion to an adherend so as to enable a drug, especially, a systemically active drug to be stably and continuously administered over an extended period. The patch preparation has a layered structure comprising a patch layer including an adhesive plaster containing a drug and a patch support, and a cover layer in this order from a side attached to a skin. In the patch preparation, a buffer material is disposed between the patch support of the patch layer and the cover layer, the cover layer has a size covering an area beyond peripheral edges of the patch layer, and a shielding film is further disposed between the cover layer and the buffer material.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
[ Cosmetics ] [ Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, topical formulations for treatment of inflammation; ] Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, transdermal patches for treatment of [ cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, vitamin imbalance, gastrointestinal conditions, skin conditions, infectious diseases, asthma, hormonal imbalance, and ] pain [ ; Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical and surgical dressings; Prescription and over-the-counter pharmaceutical preparations for use with humans and animals, namely, medical adhesive tapes ]
64.
Fentanyl-containing adhesive preparation for external use
Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains SIS, a tackifier resin that is composed of a rosin resin and terpene resin, and a softener that is composed of a plybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.
Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention provides a patch containing beraprost or a pharmacologically acceptable salt thereof, which achieves high transdermal absorption of beraprost or a pharmacologically acceptable salt thereof and has excellent formulation properties.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
Provided is a novel transdermal preparation which contains, as an active ingredient, silodosin, a salt of silodosin, tamsulosin or a salt of tamsulosin, and which is capable of maintaining a dissolved state for a long period of time and has excellent skin permeability, while exhibiting percutaneous absorption effectively and continuously. A transdermal preparation which contains: an acrylic adhesive containing an acrylic copolymer which is a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer, and which contains a carboxyl group; and at least one percutaneous absorption enhancer that is selected from the group consisting of oleyl alcohol, lauryl alcohol and lauromacrogol.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A patch containing free ropinirole (ropinirole in free form) in an adhesive base is provided, in which the patch exhibits favorable and continuous transdermal absorbability, high drug stability, and excellent adhesiveness. A transdermal absorption patch includes free ropinirole added to an adhesive base that contains a styrene-isoprene-styrene block copolymer (SIS), one or two or more tackifier resins containing a rosin-based resin, and a softener. The transdermal absorption patch is characterized in that the compounding ratio of the rosin-based resin to the free ropinirole represented as the ratio of the weight of the combined rosin-based resin to the free ropinirole is 3.5 to 8.0. In particular, a ropinirole-containing patch wherein the rosin-based resin is a hydrogenated rosin glycerol ester and the softener is liquid paraffin is provided.
Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Provided is a patch preparation having improved adhesion to an adherend so as to be able to continuously administer a drug, particularly a drug having systemic action, in a consistent fashion for an extended period. The patch preparation has a laminated structure comprising, in order from the skin-adhering side: an adhesive patch layer comprising a pressure-sensitive plaster containing a drug, and an adhesive patch support; and a cover layer, wherein the patch preparation is characterized in that a cushioning material is arranged between the cover layer and the adhesive patch support of the adhesive patch layer, the cover layer being of a size covering an area beyond the peripheral edges of the adhesive patch layer, and a masking film is further arranged between the cover layer and the cushioning material.
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis. Packaged iontophoretic systems, kits including iontophoretic devices, and methods of making iontophoretic devices are also provided.
Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis. Packaged iontophoretic systems, kits including iontophoretic devices, and methods of making iontophoretic devices are also provided.
Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject experiencing pain. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. Also provided are transdermal delivery devices configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Aspects of the invention include methods of treating withdrawal syndrome by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a non-sedative amount of dexmedetomidine to a subject diagnosed as having withdrawal syndrome. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to treat withdrawal syndrome in the subject. Also provided are transdermal delivery devices configured to deliver a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
82.
TOPICAL SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST FORMULATIONS AND METHODS OF USING THE SAME
Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.
Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.
Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A transdermal absorption preparation comprising (1) a support, and (2) a rubber-based adhesive layer comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, oleic acid, capric acid and crotamiton, wherein the rubber-based adhesive layer is formed on a surface of the support. The transdermal absorption preparation exhibits excellent transdermal absorption of the 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or salt thereof.
The present invention provides a patch containing beraprost or a pharmacologically acceptable salt thereof and having excellent percutaneous absorption of beraprost or a pharmacologically acceptable salt thereof and good formulation properties.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an α-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, α-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.
Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an α-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, α-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.
An iontophoresis patch (12) which outputs an electric current from an energizing device (14) to an external conductor comprises: a donor portion (16) that has a first contact member (34); a reference portion (18) that has a second contact member (38) and is located on the external conductor away from the donor portion (16); and an electrode body (20) that has a first electrode (42, 70, 80, 90) and a second electrode (44) and that extends across the donor portion (16) and the reference portion (18). The electrode body (20) has a single-sided wiring structure in which the first electrode (42, 70, 80, 90) and the second electrode (44) are formed by a conductive ink being printed on one side of a film (28), the printing pattern of the first electrode (42) has a gap area (43, 71, 81, 91) in which the conductive ink is not printed, and the film (28) and the first contact member (34) are transparent.
Provided is a transdermal absorption-type patch containing a serotonin receptor antagonist, which has a short transdermal absorption delay time (lag time), and in which the maximum transdermal permeation rate of the drug can be reached within a short time and the drug can disappear from circulating blood rapidly. That is, provided is a patch containing a serotonin receptor antagonist, wherein the patch contains an adhesive layer comprising a non-functional acrylic adhesive, a water-soluble organic amine, a fatty acid ester, and a serotonin receptor antagonist such as granisetron as an active ingredient.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
97.
Compositions and methods for transdermal delivery of hormones and other medicinal agents
The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
98.
COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF HORMONES AND OTHER MEDICINAL AGENTS
The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Provided is a water-based plaster in which the gel strength is maintained to an appropriate level in a step of producing the water-based plaster, and particularly in a spreading step and an aging step, and a final preparation can exhibit an optimal adhesiveness for adhering to the skin. In the water-based plaster, a water-based adhesive base containing a water-soluble polymer as a main ingredient contains a higher fatty acid which is a liquid at room temperature and a viscosity of 1,000 (mPa·s, 20° C.) or more as a crosslinking modifier. The higher fatty acid is isostearic acid, and the contained amount thereof is 1 to 10% by weight.
The purpose of the present invention is to provide an adhesive patch that is obtained by blending ropinirole, which is in a free form, in an adhesive base, said adhesive patch having good and lasting percutaneous absorption, excellent medicinal ingredient stability and excellent adhesiveness. Provided is a transdermal adhesive patch that is obtained by blending ropinirole, which is in a free form, in an adhesive base that is obtained by compounding a styrene-isoprene-styrene block copolymer (SIS), a softening agent and one or more kinds of tackifying resins each containing a rosin resin. This transdermal adhesive patch is characterized in that the blending ratio of the rosin resin to the ropinirole in a free form, namely (the blending weight of the rosin resin)/(the ropinirole in a free form) is 3.5-8.0. In particular, a ropinirole-containing adhesive patch wherein the rosin resin is a hydrogenated rosin glycerol ester and the softening agent is a liquid paraffin.
